https://endpts.com/verve-reveals-letter-from-fda-that-lays-out-conditions-to-lift-base-editing-trial-hold/
0
0
12/5/22 at 4:02pm
Organization
Endpoints News
Author
Paul Schloesser
We now know why Verve's lead candidate was placed on hold last month by US regulators. In an SEC filing, Verve laid out the FDA's conditions for lifting the hold on its lead therapy, VERVE-101. That includes submitting preclinical data about potency differenc…
Create an account
or login to join the discussion